Gottfrid Sjödahl
1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel
- Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays
- A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
- Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases
- Molecular subtype classification of urothelial carcinoma in Lynch syndrome
- 2017
- Long-term functional outcomes after radical cystectomy with ileal bladder substitute : does the definition of continence matter?
- HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
- Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder : Association with tumor stage, lymph node metastases, FDG-PET findings, and survival
- Molecular classification of urothelial carcinoma : global mRNA classification versus tumour-cell phenotype classification
- Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder